Profile data is unavailable for this security.
About the company
JFL Life Sciences Limited is an India-based pharmaceutical company. The Company's business segment comprises the manufacturing and selling of pharmaceutical products. The Company is engaged in producing and marketing a wide range of formulations. The Company has manufacturing facilities with trading and related activities extending to the global market. Its manufacturing facilities are located at Kerala, Bavla, Ahmedabad, Gujarat. The Company's main product categories include dry powder injections, tablets and capsules (B-Lactam) solid oral dosage form, tablet and capsules (general), and ORS. Its beta lactam dry powder injection products include Ampicillin Injection, Cefotaxime Sodium Injection -250 Mg, Cefazoline Sodium Injection and meropenem injection - 1 gm. Its beta lactam tablet and capsule products include Cefadroxil Tablets 500 mg and Cefadroxil Capsules 500 mg. Its general tablet and capsule products include Azithromycin Tablets - 500 mg and Ofloxacin Tablets - 200 mg.
- Revenue in INR (TTM)--
- Net income in INR--
- Incorporated2010
- Employees--
- LocationJFL Life Sciences Ltd309, Satyam Mall, Satellite RoadAHMEDABAD 380015IndiaIND
- Phone+91 7 940036595
- Websitehttps://www.jfllifesciences.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vivimed Labs Ltd | 1.47bn | -3.17bn | 410.42m | 607.00 | -- | -- | -- | 0.2783 | -38.77 | -38.77 | 17.88 | -- | -- | -- | -- | 2,429,737.00 | -- | -5.92 | -- | -8.97 | -62.46 | 33.74 | -214.73 | -14.20 | -- | -6.31 | -- | -- | -21.15 | -30.83 | -385.64 | -- | -- | -- |
| Vineet Laboratories Ltd | 1.51bn | 10.27m | 542.08m | -- | 52.97 | 1.56 | 15.29 | 0.36 | 1.11 | 1.11 | 163.46 | 37.67 | 1.29 | 2.38 | 4.51 | -- | 0.8826 | -- | 2.50 | -- | 24.35 | -- | 0.682 | -- | 0.5105 | 0.9792 | 0.5606 | -- | -29.06 | -- | -18.00 | -- | -- | -- |
| JFL Life Sciences Ltd | -100.00bn | -100.00bn | 621.41m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.63 | -- | 50.42 | -- | -- | -- |
| Mono Pharmacare Ltd | -100.00bn | -100.00bn | 699.68m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 58.12 | -- | 251.10 | -- | -- | -- |
